Silence Therapeutics (Silence Therapeutics) Days Inventory : 0.00 (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Silence Therapeutics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Silence Therapeutics's Average Total Inventories for the three months ended in Mar. 2024 was $0.00 Mil. Silence Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $2.81 Mil. Hence, Silence Therapeutics's Days Inventory for the three months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Silence Therapeutics's Days Inventory or its related term are showing as below:

SLNCF's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 193.86
* Ranked among companies with meaningful Days Inventory only.

Silence Therapeutics's Days Inventory stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Silence Therapeutics's Inventory-to-Revenue for the three months ended in Mar. 2024 was 0.00.

Silence Therapeutics Days Inventory Historical Data

The historical data trend for Silence Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Days Inventory Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

Silence Therapeutics Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Silence Therapeutics's Days Inventory

For the Biotechnology subindustry, Silence Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Days Inventory falls into.

Silence Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Silence Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	13.061	*	365
=	0					/	13.061	*	365
=	0.00

Silence Therapeutics's Days Inventory for the quarter that ended in Mar. 2024 is calculated as:

	Days Inventory (Q: Mar. 2024 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	2.812	*	365 / 4
=	0					/	2.812	*	365 / 4
=	0.00

Silence Therapeutics (OTCPK:SLNCF) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Silence Therapeutics's Inventory Turnover for the three months ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	2.812	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Silence Therapeutics's Inventory to Revenue for the three months ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	15.764
	=	0.00

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Silence Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics (Silence Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (OTCPK:SLNCF) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

SLN:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.